Geode Capital Management LLC grew its holdings in shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) by 9.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 819,415 shares of the biotechnology company’s stock after purchasing an additional 71,665 shares during the quarter. Geode Capital Management LLC owned approximately 0.83% of BioCryst Pharmaceuticals worth $4,023,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Janus Henderson Group PLC acquired a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at about $23,762,000. BlackRock Inc. boosted its position in shares of BioCryst Pharmaceuticals by 15.0% during the 4th quarter. BlackRock Inc. now owns 7,614,280 shares of the biotechnology company’s stock valued at $37,386,000 after acquiring an additional 993,100 shares during the last quarter. Eversept Partners LLC acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $974,000. Schwab Charles Investment Management Inc. boosted its position in shares of BioCryst Pharmaceuticals by 55.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 496,792 shares of the biotechnology company’s stock valued at $2,440,000 after acquiring an additional 176,714 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of BioCryst Pharmaceuticals by 25.4% during the 4th quarter. Bank of New York Mellon Corp now owns 464,191 shares of the biotechnology company’s stock valued at $2,279,000 after acquiring an additional 94,160 shares during the last quarter. 91.45% of the stock is currently owned by institutional investors.
NASDAQ BCRX opened at $4.84 on Friday. BioCryst Pharmaceuticals has a 12 month low of $3.95 and a 12 month high of $7.39. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.68 and a current ratio of 1.68. The stock has a market capitalization of $511.28, a price-to-earnings ratio of -6.21 and a beta of 2.71.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.06). BioCryst Pharmaceuticals had a negative net margin of 261.18% and a negative return on equity of 106.53%. The company had revenue of $3.89 million during the quarter, compared to analyst estimates of $6.07 million. During the same period in the previous year, the company earned ($0.06) EPS. The company’s quarterly revenue was down 56.7% compared to the same quarter last year. analysts predict that BioCryst Pharmaceuticals will post -0.79 EPS for the current fiscal year.
BCRX has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, January 23rd. BidaskClub raised shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 6th. Royal Bank of Canada raised shares of BioCryst Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a research report on Tuesday, January 2nd. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, March 5th. Finally, ValuEngine cut shares of BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, February 14th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $8.29.
WARNING: This news story was published by Macon Daily and is the sole property of of Macon Daily. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://macondaily.com/2018/04/20/geode-capital-management-llc-acquires-71665-shares-of-biocryst-pharmaceuticals-bcrx.html.
BioCryst Pharmaceuticals Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.